{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T19:48:14Z","timestamp":1781552894732,"version":"3.54.5"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This article underscores the critical role of social workers in harnessing the potential therapeutic benefits of psilocybin for treating major depressive disorder (MDD) and substance use disorder (SUD). Contemporary treatments for MDD often have side effects, and the success rate for SUD treatments remains low. The pervasiveness of MDD, combined with the challenges in treating SUD, highlights a need for innovative treatments. This article provides an overview of the resurgence of literature over the past two decades that illuminates the therapeutic promise of psilocybin for mental health treatment; clinical trials elucidate the efficacy of psilocybin-assisted therapy in mitigating MDD and demonstrate great promise in reducing SUD symptoms. The long-lasting posttreatment effect emphasizes its potential as a novel treatment modality. Furthermore, psilocybin\u2019s recognition as a \u201cbreakthrough therapy\u201d by the U.S. Food and Drug Administration (FDA) and the accelerating pace of psychedelic reform bills indicate growing acceptance and interest in its therapeutic capacities. Psilocybin-assisted therapy emerges as a potent treatment option, showcasing remarkable effectiveness even after a single dose. Recommendations and pathways for social workers to be involved in psilocybin-assisted therapy investigation, advocacy, and implementation are provided.<\/jats:p>","DOI":"10.1093\/sw\/swae019","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T22:53:50Z","timestamp":1714690430000},"page":"297-302","source":"Crossref","is-referenced-by-count":2,"title":["At the Forefront: Social Workers\u2019 Role in Psilocybin Treatment for Depression and Substance Misuse"],"prefix":"10.1093","volume":"69","author":[{"given":"Claire","family":"Parker","sequence":"first","affiliation":[{"name":"School of Social Work, University of Texas at Arlington Claire Parker is a social work student, , 501 West Mitchell Street, Arlington, TX 76010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany Marie","family":"Wood","sequence":"additional","affiliation":[{"name":"School of Social Work, University of Texas at Arlington Bethany Marie Wood, PhD, CSW, is assistant professor, , Arlington, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"2024062116473417400_swae019-B1","author":"American Psychiatric Association","year":"2022"},{"key":"2024062116473417400_swae019-B2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/00952990.2016.1200060","article-title":"It\u2019s time to take psilocybin seriously as a possible treatment for substance use disorders [Commentaries]","volume":"43","author":"Bogenschutz","year":"2017","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"2024062116473417400_swae019-B3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"Journal of Psychopharmacology"},{"key":"2024062116473417400_swae019-B4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"2024062116473417400_swae019-B5","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of escalating doses of oral psilocybin in healthy adults","volume":"56","author":"Brown","year":"2017","journal-title":"Clinical Pharmacokinetics"},{"key":"2024062116473417400_swae019-B6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"key":"2024062116473417400_swae019-B7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.nrleng.2011.07.010","article-title":"Hallucinogenic drugs in pre-Columbian Mesoamerican cultures","volume":"30","author":"Carod-Artal","year":"2015","journal-title":"Neurolog\u00eda (English Edition)"},{"key":"2024062116473417400_swae019-B8","volume-title":"COMPASS Pathways: American Medical Association releases language of first new current procedural terminology code for psychedelic therapies","author":"COMPASS Pathways","year":"2023"},{"key":"2024062116473417400_swae019-B9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/acps.13335","article-title":"The effects of psychotherapies for depression on response, remission, reliable change, and deterioration: A meta-analysis","volume":"144","author":"Cuijpers","year":"2021","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"2024062116473417400_swae019-B10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2024062116473417400_swae019-B11","doi-asserted-by":"crossref","first-page":"9791","DOI":"10.1007\/s11033-020-06009-x","article-title":"Psychedelics as an emerging novel intervention in the treatment of substance use disorder: A review","volume":"47","author":"DiVito","year":"2020","journal-title":"Molecular Biology Reports"},{"key":"2024062116473417400_swae019-B12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/jcp.0b013e31815152a5","article-title":"Selective serotonin reuptake inhibitor discontinuation: Side effects and other factors that influence medication adherence","volume":"27","author":"Goethe","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"2024062116473417400_swae019-B13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4088\/JCP.14m09298","article-title":"The economic burden of adults with major depressive disorder in the United States (2005 and 2010)","volume":"76","author":"Greenberg","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"key":"2024062116473417400_swae019-B14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajp.2018.01.004","article-title":"Electroconvulsive therapy among elderly patients: A study from tertiary care centre in north India","volume":"31","author":"Grover","year":"2018","journal-title":"Asian Journal of Psychiatry"},{"key":"2024062116473417400_swae019-B15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"Journal of Psychopharmacology"},{"key":"2024062116473417400_swae019-B16","author":"Haridy","year":"2018"},{"key":"2024062116473417400_swae019-B17","author":"Holyanova","year":"2023"},{"key":"2024062116473417400_swae019-B18","author":"Jacobs","year":"2022"},{"key":"2024062116473417400_swae019-B19","author":"Jaeger","year":"2023"},{"key":"2024062116473417400_swae019-B20","author":"Jaeger","year":"2023"},{"key":"2024062116473417400_swae019-B21","author":"Jaeger","year":"2023"},{"key":"2024062116473417400_swae019-B22","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"Journal of Psychopharmacology"},{"key":"2024062116473417400_swae019-B23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"2024062116473417400_swae019-B24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"2024062116473417400_swae019-B25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hbm.23347","article-title":"Altered functional network architecture in orbitofronto-striato-thalamic circuit of unmedicated patients with obsessive-compulsive disorder","volume":"38","author":"Jung","year":"2017","journal-title":"Human Brain Mapping"},{"key":"2024062116473417400_swae019-B26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1021\/acsmedchemlett.0c00048","article-title":"Psilocybin therapeutic research: The present and future paradigm","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"2024062116473417400_swae019-B27","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/add.13806","article-title":"Extended treatment for cigarette smoking cessation: A randomized control trial","volume":"112","author":"Laude","year":"2017","journal-title":"Addiction"},{"key":"2024062116473417400_swae019-B28","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1040217","article-title":"Therapeutic use of psilocybin: Practical considerations for dosing and administration","volume":"13","author":"MacCallum","year":"2022","journal-title":"Frontiers in Psychiatry"},{"key":"2024062116473417400_swae019-B29","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"2024062116473417400_swae019-B30","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-018-1824-6","article-title":"Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature","volume":"18","author":"Michaels","year":"2018","journal-title":"BMC Psychiatry"},{"key":"2024062116473417400_swae019-B31","author":"National Association of Social Workers","year":"2021"},{"key":"2024062116473417400_swae019-B32","volume-title":"Average cost of drug rehab [2023]: By type, state & more","author":"National Center for Drug Abuse Statistics","year":"2023"},{"key":"2024062116473417400_swae019-B33","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2023.1125780","article-title":"Psychedelics and neonihilism: Connectedness in a meaningless world","volume":"14","author":"Plesa","year":"2023","journal-title":"Frontiers in Psychology"},{"key":"2024062116473417400_swae019-B34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"2024062116473417400_swae019-B35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5040\/9798400607196.ch-007","volume-title":"Advances in psychedelic medicine: State-of-the-art therapeutic applications","author":"Rao","year":"2019"},{"key":"2024062116473417400_swae019-B36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic drug legislative reform and legalization in the US","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"2024062116473417400_swae019-B37","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11920-011-0224-0","article-title":"New findings on biological factors predicting addiction relapse vulnerability","volume":"13","author":"Sinha","year":"2011","journal-title":"Current Psychiatry Reports"},{"key":"2024062116473417400_swae019-B38","doi-asserted-by":"crossref","DOI":"10.1186\/s12875-015-0277-y","article-title":"Informal carers\u2019 health-related quality of life and patient experience in primary care: Evidence from 195,364 carers in England responding to a national survey","volume":"16","author":"Thomas","year":"2015","journal-title":"BMC Family Practice"},{"key":"2024062116473417400_swae019-B39","author":"U.S. Bureau of Labor Statistics","year":"2023"},{"key":"2024062116473417400_swae019-B40","volume-title":"Major depression","author":"U.S. Department of Health and Human Services","year":"2021"},{"key":"2024062116473417400_swae019-B41","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1134454","article-title":"Therapeutic effect of psilocybin in addiction: A systematic review","volume":"14","author":"van der Meer","year":"2023","journal-title":"Frontiers in Psychiatry"},{"key":"2024062116473417400_swae019-B42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/19371918.2013.759033","article-title":"Social workers and delivery of evidence-based psychosocial treatments for substance use disorders","volume":"28","author":"Wells","year":"2013","journal-title":"Social Work in Public Health"},{"key":"2024062116473417400_swae019-B43","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jamda.2009.04.004","article-title":"Beyond the medical model: The culture change revolution in long-term care","volume":"10","author":"White-Chu","year":"2009","journal-title":"Journal of the American Medical Directors Association"},{"key":"2024062116473417400_swae019-B44","article-title":"Analysis of psilocybin-assisted therapy in medicine: A narrative review","volume":"14","author":"Ziff","year":"2022","journal-title":"Cureus"}],"container-title":["Social Work"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/sw\/article-pdf\/69\/3\/297\/58301012\/swae019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sw\/article-pdf\/69\/3\/297\/58301012\/swae019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T16:48:31Z","timestamp":1718988511000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sw\/article\/69\/3\/297\/7663546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,2]]},"published-print":{"date-parts":[[2024,6,21]]}},"URL":"https:\/\/doi.org\/10.1093\/sw\/swae019","relation":{},"ISSN":["0037-8046","1545-6846"],"issn-type":[{"value":"0037-8046","type":"print"},{"value":"1545-6846","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,5,2]]}}}